FDA-approved drug helps treat rare immunologic disease, study finds

(NIH/National Institute of Allergy and Infectious Diseases) Adding the injectable drug mepolizumab to standard treatment for eosinophilic granulomatosis with polyangiitis (EGPA), a rare immunologic disease, significantly improved clinical outcomes among participants in an advanced clinical trial, scientists report.